Efalizumab: Continuous therapy for chronic psoriasis

Expert Opinion on Biological Therapy

Volumn 5, Issue 3, 2005, Pages 393-403

  Cather, Jennifer Clay ^a   Menter, Alan ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Continuous therapy; Efalizumab; Monoclonal antibody; Psoriasis

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; EFALIZUMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ABSCESS; ASEPTIC MENINGITIS; BRONCHITIS; CELLULITIS; CHILL; CLINICAL TRIAL; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EUROPE; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROENTERITIS; GRANULOMATOUS INFLAMMATION; HEADACHE; HUMAN; INFECTION; LEGIONNAIRE DISEASE; LONG TERM CARE; MAINTENANCE THERAPY; MYALGIA; NAUSEA; PNEUMONIA; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHINITIS; SEPSIS; SINUSITIS; SKIN CANCER; SPONDYLITIS; THROMBOCYTOPENIA; TUBERCULOSIS; UNITED STATES; VOMITING;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DERMATOLOGIC AGENTS; HUMANS; PSORIASIS; TIME;

EID: 17144386968     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.3.393     Document Type: Review

References (49)

1. NALDI L: Epidemiology of psoriasis. Curr. Drug Targets Inflamm. Allergy (2004) 3(2):121-128.
2. STERN RS, NIJSTEN T, FELDMAN SR, MARGOLIS DJ, ROLSTAD T: Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J. Investig. Dermatol. Symp. Proc. (2004) 9(2):136-139.
3. RAPP SR, FELDMAN SR, EXUM ML, FLEISCHER AB JR, REBOUSSIN DM: Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. (1999) 41(3 Pt 1):401-407.
4. DE KORTE J, SPRANGERS MA, MOMBERS FM, BOS JD: Quality of life in patients with psoriasis: a systematic literature review. J. Investig. Dermatol. Symp. Proc. (2004) 9(2):140-147.
5. STERRY W, BARKER J, BOEHNCKE WH et al.: Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br. J. Dermatol. (2004) 151(Suppl.):693-617.
6. NALDI L, SVENSSON A, DIEPGEN T et al.: Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J. Invest. Dermatol. (2003) 120(5):738-741.
7. YAMAUCHI PS, RIZK D, KORMEILI T, PATNAIK R, LOWE NJ: Current systemic therapies for psoriasis: where are we now? J. Am. Acad. Dermatol. (2003) 49(2 Suppl.):S66-S77.
8. MENTER MA, ABRAMOVITS W: Rational, sequential and combination regimens in the treatment of psoriasis. Dermatol. Ther. (1999):1188-1195.
9. WEINSTEIN GD, WHITE GM: An approach to the treatment of moderate to severe psoriasis with rotational therapy. J. Am. Acad. Dermatol. (1993) 28(3):454-459.
10. KRUEGER G, KOO J, LEBWOHL M, MENTER A, STERN RS, ROLSTAD T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. (2001) 137(3):280-284.
11. SALONEN SH: The EUROPSO psoriasis patient study: treatment history and satisfaction reported by 17,990 members of European psoriasis patient associations. Poster presented at: Spring Symposium of the European Academy of Dermatology and Venereology. Malta (2003).
12. VAN DE KERKHOF P, SALONEN SH: Large-scale European survey of quality of life in patients with psoriasis: second phase results on quality of life and treatment reported by 7525 members of European psoriasis patient associations. Poster presented at: II Spring Symposium of the European Academy of Dermatology and Venereology. Budapest, Hungary (2004).
13. KANITAKIS J, BUTNARU AC, CLAUDY A: Novel biological immunotherapies for psoriasis. Expert Opin. Investig. Drugs (2003) 12(7):1111-1121.
14. NICKOLOFF BJ, NESTLE FO: Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. (2004) 113(12):1664-1675.
15. PRINZ JC: The role of T cells in psoriasis. J. Eur. Acad. Dermatol. Venereol. (2003) 17(3):257-270.
16. KRUEGER JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. (2002) 46(1):1-23.
17. JULLIEN D, PRINZ JC, LANGLEY RGB et al.: T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva™): Mechanisms of action. Dermatology (2004) 208:297-306.
18. CATHER JC, CATHER JC, MENTER A: Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin. Biol. Ther. (2003) 3(2):361-370.
19. DEDRICK RL, BAUER R, BOHMANN D, WALICKE P, GAROVOY MR: Pharmacokinetics and pharmacodynamics of subcutaneously administered efalizumab (anti-CD11a) in psoriasis subjects. Poster presented at: 59th Annual Meeting of the American Academy of Dermatology. Washington, DC, USA (2001) Poster #505.
20. GOTTLIEB AB, MILLER B, LOWE N et al.: Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis. J. Cutan. Med. Surg. (2003) 7(3): 198-207.
21. LEONARDI CL, GOTTLIEB A, MILLER B et al.: Efalizumab (anti-CD11a): results of a 12 week trial of subcutaneous administration in patients with moderate to severe plaque psoriasis. Poster presented at: 59th Annual Meeting of the American Academy of Dermatology. Washington, DC, USA (2001) Poster #506.
22. VUGMEYSTER Y, HOWELL K, CHAMIAN F et al.: Efalizumab modulates an array of adhesion-related and activation-controlling surface proteins on T lymphocytes and inhibits anti-CD3-induced T-cell activation in adults with moderate to severe psoriasis. Poster presented at: International Investigative Dermatology Annual Meeting. Miami, FL, USA (2004) Poster #47.
23. MORTENSEN DL, WALICKE PA, GOTTLIEB AB et al.: The pharmacokinettcs and pharmacodynamics of efalizumab following 12 weeks of subcutaneous treatment in patients with moderate to severe plaque psoriasis in a Phase I, open-label, multi-center study. Poster presenred at: International Investigative Dermatology Annual Meeting. Miami, FL, USA (2003) Poster #379.
24. PAPP K, MILLER B, CARO I et al.: Efalizumab (anti-CD11a) retreatment: final results from an open-label study in psoriasis. Poster presented at: 61st Annual Meeting of the American Academy of Dermatology. San Francisco, CA, USA (2003) Poster #614.
25. GORDON KB, PAPP KA, HAMILTON TK et al.: Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA (2003) 290(23):3073-3080.
26. LEBWOHL M, TYRING SK, HAMILTON TK et al.: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. (2003) 349(21):2004-2013.
27. LEONARDI CL, PAPP KA, GORDON KB et al.: Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized Phase III trial. J. Am. Acad. Dermatol. (2005) (In Press).
28. MENTER A, GORDON KB, CAREY W et al.: Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch. Dermatol. (2005) 141(1):31-38.
29. PAPP KA, SOBELL J, TOTH D et al.: Safety of subcutaneous efalizumab therapy in patients with moderate to severe plaque psoriasis. Poster presented at: American Academy of Dermatology Summer Meeting. Chicago, IL, USA (2003) Poster #41.
30. GORDON K, PARISER D, LANGLEY R et al.: Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: pooled results from randomized Phase III trials Poster presented at: 62nd Annual Meeting of the American Academy of Dermatology. Washington DC, USA (2004) Poster #4.
31. STERRY W, DUBERTRET L, PAPP K, CHIMENTI S, LARSEN CG: Efalizumab for patients with moderate to severe chronic plaque psoriasis: results of the international, randomized, controlled Phase III clinical experience Raptiva (CLEAR) trial. Poster presented at: 34th Annual Meeting of the European Society for Dermatological Research. Vienna, Austria (2004) Poster #386.
32. GOTTLIEB AB, GORDON KB, LEBWOHL MG et al.: Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J. Drugs Dermatol. (2004) 3(6):614-624.
33. GOTTLIEB A, HAMILTON T, CARO I et al.: Efficacy and safety outcomes of extended efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: an update. Poster presented at: American Academy of Dermatology Summer Meeting. New York, NY, USA (2004) Poster #77.
34. CHOI J, KOO JY: Quality of life issues in psoriasis. J. Am. Acad. Dermatol. (2003) 49(2 Suppl.):S57-S61.
35. SHIKIAR R, BRESNAHAN BW, STONE SP, THOMPSON C, KOO J, REVICKI DA: Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual. Life Outcomes (2003) 1:53.
36. FELDMAN SR, MILLER B, POWERS J et al.: Subcutaneous (SC) efalizumab (anti-CD11a) improves quality of life in patients with moderate to severe plaque psoriasis. Poster presented at: 60th Annual Meeting of the American Academy of Dermatology. New Orleans, LO, USA (2002) Poster #587.
37. FELDMAN SR, CAREY W, GOLDMAN M et al.: Subcutaneous (SC) efalizumab (anti-CD11) significantly improves patient reported symptoms in patients with moderate to severe plaque psoriasis. Poster presented at: Summer Meeting of the American Academy of Dermatology. New York, NY, USA (2002) Poster #53.
38. MENTER A, KOSINSKI M, BRESNAHAN BW, PAPP KA, WARE JE JR: Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J. Drugs Dermatol. (2004) 3(1):27-38.
39. ORTONNE JP, STERRY W, SHEAR N et al.: Impact of efalizumab on health-related quality-of-life outcomes in patients with moderate to severe chronic plaque psoriasis: results of the international, randomised, placebo-controlled Phase III clinical experience acquired with Raptiva (CLEAR) Trial. Poster presented at: 34th Annual Meeting of the European Society for Dermatological Research. Vienna, Austria (2004) Poster #397.
40. CAREY W, MENTER A, GILBERT M et al.: Effects of 24 weeks of continuous efalizumab therapy on health-related quality of life in patients with moderate to severe chronic plaque psoriasis. Poster presented at: II Spring Symposium of the European Academy of Dermatology and Venereology. Budapest, Hungary (2004).
41. CHAUDHARI U, ROMANO P, MULCAHY LD, DOOLEY LT, BAKER DG, GOTTLIEB AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 357(9271):1842-1847.
42. KRUEGER GG, PAPP KA, STOUGH DB, LOVEN KH, GULLIVER WP, ELLIS CN: A randomized, double-blind, placebo-controlled Phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. (2002) 47(6):821-833.
43. LEBWOHL M, CHRISTOPHERS E, LANGLEY R, ORTONNE JP, ROBERTS J, GRIFFITHS CE: An international, randomized, double-blind, placebo-controlled Phase III trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol. (2003) 139(6):719-727.
44. LEONARDI CL, POWERS JL, MATHESON RT et al.: Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. (2003) 349(21):2014-2022.
45. GENENTECH, INC.: Raptiva™ (efalizumab) package insert. South San Francisco, CA, USA (2003).
46. GORDON KB, KOO JYM, FELDMAN SR et al.: Definitions of measures of effect duration for psoriasis treatments. Psoriasis Forum (2002) 8(3): 1-5.
47. MENTER A, KARDATZKE D, RUNDLE AC, KWON P, GAROVOY MR, LEONARDI CL: Incidence and prevention of rebound upon efalizumab discontinuation. Poster presented at: 10th International Psoriasis Symposium. Toronto, Canada (2004).
48. RENTENAAR RJ, HEYDENDAEL VM, VAN DIEPEN FN, DE RIE MA, TEN BERGE IJ: Systemic treatment with either cyclosporin A or methotrexate does not influence the T helper 1/T helper 2 balance in psoriatic patients. J. Clin. Immunol. (2004) 24(4):361-369.
49. GUENTHER L, LANGLEY R, SHEAR NH et al.: Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. Poster presented at: 10th International Psoriasis Symposium. Toronto, Canada (2004) Poster #27.